Disc Medicine posts smaller-than-expected Q1 net loss

Disc Medicine, Inc.

Disc Medicine, Inc.

IRON

0.00


Overview

  • US biopharmaceutical firm's Q1 loss was smaller than expected

  • Company ended Q1 with $730 mln in cash, funding runway into 2029


Outlook

  • Company says current cash position expected to fund operations into 2029


Result Drivers

  • PIPELINE ADVANCEMENT - Higher R&D expenses driven by progress in bitopertin clinical studies, advancement of DISC-0974 and DISC-3405 programs, and increased headcount

  • COMMERCIALIZATION PREPARATION - SG&A expenses rose due to increased headcount and building infrastructure to support potential commercialization


Company press release: ID:nGNX9RCSDR


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

Beat

-$63.50 mln

-$67.08 mln (6 Analysts)

Q1 Basic EPS

Beat

-$1.65

-$1.71 (10 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Disc Medicine Inc is $100.00, about 47.8% above its May 4 closing price of $67.64


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.